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The calculation of utilization increases reflects the change
in the aggregate number of prescriptions filled. The cal-
culation of annual increase in expenditures reflects the
change in expenditure from an old set of drugs to a new
set. To estimate the impact of pipeline drugs, case scenar-
ios were performed around HCFA’s baseline projections
for future drug trends. The compounded, annual, growth-
rate decrease of new drug approvals was used as a lower
bound, while a constant increase in the pipeline projection
provided the upper bound.
RESULTS: Historically, slightly less than one-third of the
increase in drug expenditure was due to price increases
on existing drugs, approximately one-third was due to in-
creases in the utilization of existing drugs, and slightly
more than one-third was due to product shift. Based on
our data, the historical increase in expenditures was 15%
for all drugs, 25% for newer drugs and 7% for older
drugs. Our lower and upper bound scenarios projected
national drug expenditures of $191.56 billion and
$215.62 billion, respectively, for 2004.
CONCLUSION: The impact of pipeline drugs on future
drug trends is significant. There is considerable variation
surrounding the impact of pipeline drugs on future drug
expenditures based on several plausible scenarios.
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If the “total” costs of a disease, such as cancer, are to be
accurately quantified, out-of-pocket expenditures (OOPE)
made by patients and caregivers must be added to costs
incurred by third party payers (direct medical) and em-
ployers (lost productivity). Prior studies of OOPE by the
elderly used small geographically restricted samples and
narrow patient subgroups.
OBJECTIVES: To rigorously quantify OOPE for individ-
uals older than 70 years in the United States. To empha-
size cancer-related OOPE, three patient cohorts were ex-
amined: 1) no cancer (No CA); 2) history of cancer but
not undergoing treatment (CA/No Tx), and 3) undergo-
ing active cancer treatment (CA/Tx).
METHODS: Data from the Asset and Health Dynamics
Study, a nationally representative, longitudinal survey of
community-dwelling elderly were used. Respondents de-
noted cancer status and reported OOPE over two years
for: 1) nursing home/hospitals; 2) doctor visits; 3) pre-
scription drugs, and 4) “special” services. Using a multi-
variable two-part regression model to control for differ-
ences in co-morbidity, health status, living situation, and
sociodemographics, the additional cancer-related OOPE
was estimated.
RESULTS: Of the 6576 respondents, 5553 (84%) re-
ported No CA, 843 (13%) reported CA/No Tx, and 180
(3%) reported CA/Tx. Cancer diagnosis and current can-
cer treatment were significant predictors of increased
OOPE compared to no cancer. The mean annual OOPE
for No CA, CA/No Tx, and CA/Tx groups was US$1900,
US$2400, and US$3300, respectively (p  .001). Hospi-
tals (US$1400/yr) and prescription drugs (US$1100/yr)
were the largest OOPE components for the CA/Tx group.
The incremental OOPE for CA/No Tx and CA/Tx pa-
tients approximates US$1.5 billion annually.
CONCLUSIONS: OOPE for elderly individuals with a
history of cancer or ongoing therapy are substantial and
significantly greater than for those without cancer. If
OOPE remain unaccounted for, total costs of cancer will
be consistently underestimated. Economic evaluations of
interventions aimed at cancer prevention and treatment
must account for OOPE.
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OBJECTIVE: The aim of this study was to validate a self-
completed questionnaire in Upper Limb Lymphoedema.
METHODS: A qualitative survey was conducted to iden-
tify patients’ complaints. This questionnaire was admin-
istered to 154 patients. Principal component analysis was
used to identify dimensions. A validation study was con-
ducted in 304 patients. Six instruments have been used in
the case report form: volume differences between the
healthy and the affected arms; composite symptom scales
completed by clinicians from patient interviews; ULL-27
and SF-36 scales completed by patients; overall opinion
of doctors and patients. Internal validity was checked
through factorial analysis. Trait validity was investigated
by correlating the domains rated with ULL-27 with the
SF-36 scale. Nomologic validity was tested by comparing
the means of the ULL-27 subscales across severity stages.
Sensitivity was tested only in patients with progressive
disease between D0 and D28 by comparing mean sub-scores
for the ULL-27 scale and by calculating the effect size.
RESULTS: Three hundred four patients were included in
the study. Factorial analysis isolated three dimensions:
physical (15 items), psychological (7 items), and social
withdrawal (5 items). The Cronbach coefficients are
greater than 0.80 for all dimensions. The Spearman cor-
relations clearly distinguish the different life domains
from each other. At D0 the physical and social dimen-
sions of ULL-27 scale were significantly correlated with
severity of illness but it was not the case for the psycho-
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logical dimension. Correlation coefficients in patients
clinically stable between D0 and D28; were all greater
than 0.84 for all dimensions of ULL-27. The sensitivity
analysis between D0 and D28 in patients with active dis-
ease demonstrated significant differences between mean
scores for all ULL-27 dimensions.
CONCLUSION: Volume of oedema poorly reflects the
impact of the illness upon the patient. The ULL- 27 scale
seems to be a consistent instrument.
CN6
MEN’S PREFERENCES FOR THE CONSERVATIVE 
MANAGEMENT OF NON-METASTATIC 
PROSTATE CANCER: THE USE OF 
CONJOINT ANALYSIS
Sculpher M1, Bryan S2, Emberton M3, Fry P3, de Winter P3, 
Payne H3
1University of York, York, UK; 2Birmingham University, 
Birmingham, UK; 3Middlsex Hospital, London, UK
OBJECTIVES: Selecting conservative therapies for men
with non-metastatic prostate cancer involves trade-offs
between treatment attributes. An interview-based survey
using conjoint analysis was undertaken to establish
which treatment attributes are important to men in se-
lecting treatments, and how attributes are traded off.
METHODS: On the basis a pilot study, eight treatment-
related attributes were selected for the survey: diarrhea;
hot flushes; ability to maintain an erection; breast swell-
ing/tenderness; physical energy; sex drive; life expect-
ancy, and out-of-pocket personal costs. A discrete choice
preference elicitation mechanism was used. One hundred
eighty men with non-metastatic prostate cancer from two
London hospitals were invited to participate. Of these,
129 men, mean age of 70 years, 58% T-stage 1 or 2 at di-
agnosis, were interviewed. Data were analyzed using ran-
dom effects probit models.
RESULTS: On average, men’s responses to the conjoint
questions were sensitive to variation in the levels of all at-
tributes (p  .01) and coefficient signs on all attributes
were as expected. A statistically significant interaction
was shown which indicated that the attribute ability ‘to
maintain an erection’ was less important to older men (p 
.001). Most men were willing to make trade-offs between
avoiding side effects and both losses in life expectancy
and out-of-pocket costs. In terms of the former, they
were, on average, most willing to forgo life expectancy to
avoid limitations in physical energy (mean of 3.01
months), and least willing to trade life expectancy to
avoid hot flushes (mean of 0.58 months to move from
‘moderate’ to ‘mild’ or ‘mild’ to ‘none’).
CONCLUSIONS: Men with prostate cancer are willing
and able to participate in a relatively complex exercise
that weighs-up the benefits and harms of various conser-
vative treatments for their condition, and to make trade-
offs between attributes. The results provide an indication
of the relative importance of different aspects of treat-
ment to patients with prostate cancer.
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OBJECTIVE: To compare patients’ own global health as-
sessment item of the SF-36 (SF-1) and investigators’ glo-
bal health assessment (GLBHLT) with values calculated
for Health Utilities Index (HUI-III) and SF-36 preference-
based (SF-6D), in patients with coronary artery disease
(CAD). SF-1 is considered a coarse measure for patients’
own health assessment while GLBHLT is a widely used
clinical-trials endpoint.
METHODS: Baseline data of the SF-36, HUI-III and
GLBHLT were collected for 331 patients enrolled in a
double-blind, multinational, phase III clinical trial. Both
the SF-1 and GLBHLT rate patients’ health on a scale of
one to five, where one is excellent and five is poor.
RESULTS: Correlation coefficients (r) between the SF-1
and HUI-III, and the SF-1 and SF-6D were 0.501, 0.508,
respectively (p  .001). An r  0.27 between the SF-1 and
GLBHLT was found significant, albeit the magnitude
was almost half of those calculated for the SF-1 and SF-6D
or the SF-1 and HUI-III. Calculated SF-6D and HUI-III
values for GLBHLT  1 (excellent) were 0.74 and 0.74
compared with the corresponding SF-1 values of 0.81
and 0.83, respectively. Also the SF-6D and HUI-III values
for GLBHLT  5 (poor) were 0.59 and 0.43 compared
with the corresponding SF-1 values of 0.54 and 0.21, re-
spectively.
CONCLUSION: The SF-1 as a rough estimate of the pa-
tient’s own health, yielded a stronger correlation with
utilities calculated for HUI-III and SF-6D while GL-
BHLT, considered a routine measure in clinical trials,
yielded much weaker correlation. Confirmation of these
findings is needed to assess if GLBHLT is a fair represen-
tation of the health of patients with CAD.
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OBJECTIVES: Obesity is a very common condition in
type 2 diabetic patients. Treating obesity may enhance
hypoglycemic treatment and, thus, may contribute to a
reduction in long-term microvascular and macrovascular
